Physician profile
Dorie Weaver
NPI 1548984958
$782.85
in general payments reported to CMS, 2019-2025
11 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $175 · 2024: $451 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $782.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $331.44 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $200.48 | 2024-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neos Therapeutics, Lp | $42.79 | 2023-2024 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $40.82 | 2024 | Xelstrym |
| Axsome Therapeutics, INC. | $32.38 | 2023 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $31.99 | 2023-2024 | Trintellix |
| Corium, LLC | $27.96 | 2023 | Azstarys |
| Alkermes, INC. | $22.87 | 2024 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $19.43 | 2023 | Hetlioz, Fanapt |
| Supernus Pharmaceuticals, INC. | $19.13 | 2024 | Qelbree |
| Idorsia Pharmaceuticals US INC | $13.56 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorie Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.